- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02787434
Addressing Prostate Cancer Information Disparities With eHealth Technology (PCSPrep)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
STUDY AIMS AIM 1: Among AA men ages 45-70, estimate the impact of PCSPrep on primary outcomes: (a) knowledge; (b) confidence in ability to make informed decisions and communicate with provider; (c) consistency between values & PCS preferences.
AIM 2: Among primary care providers, to assess secondary outcomes: (a) perceptions regarding patient engagement in SDM; and (b) concordance with patient's ratings of SDM.
AIM 3: Among patients, providers and clinic staff, document the feasibility and acceptability of integrating PCSPrep into primary care practices.
RECRUITMENT & ENROLLMENT
Primary Care Providers Recruitment:
PCPs eligible to participate will be Emory Health Care practitioners who see at least 20 potentially eligible patients. These PCPs will be sent information from the Investigator Team and Clinic Director explaining the study We will use effective clinician recruitment procedures established in our prior work, including presentations at standing clinician meetings, meeting individually with providers, and being on site to answer questions. Ten PCPs who consent to participate will complete a brief survey following the visit from each of their enrolled patients, and allow these clinical encounters to be audio-recorded. See appendix B for post encounter survey for providers. As is standard in studies involving physicians, a financial incentive will be provided following completion of post-visit data collection for each patient when allowable and not in conflict with federal regulations. In the case of the VA hospital system, providers are not allowed to take financial incentives for research, so they will not receive this. Following the visit from each of their enrolled patients, providers will respond to a brief, online survey about the extent to which they involved the patient in the SDM process, and their perceptions regarding the quality of the communication about PCS. Total provider time in the study is estimated at 120 minutes (up to 15 enrolled patients x 10 minutes per post-encounter survey + 20 minutes of informed consent discussions).
Patient Recruitment and Enrollment:
The study will enroll AA men (age 45-70) who have not undergone prostate cancer screening (PCS) in the prior 3 years. Additional eligibility criteria will include: (1) self-reported AA race/ethnicity; (2) age 45-70; (3) English speaking. Exclusion criteria will include: personal history of prostate cancer (CaP), life expectancy of <10 years as determined by the primary care provider (PCP); or serious psychiatric conditions or cognitive impairment. Identification and recruitment of patients will be conducted by the Clinical Research Associate (CRA) under supervision of the investigators and in partnership with PCP's who opt to participate. Electronic medical records (EMR) and scheduling systems may be used to identify potentially eligible men who are scheduled for a non-acute, routine medical visit with a participating PCP during the enrollment period (i.e., Dr. Filson will access his EMR account and supervise all viewing by the CRA). See appendix D for Patient recruitment letter. Two weeks prior to a scheduled visit, eligible men will be mailed study information and an opt-out card informing them that they will be contacted by phone. Men who do not opt out will be called by the CRA, screened for eligibility, and provided with information about the study procedures. See appendix E for telephone recruitment script. Men interested in participating will be asked to arrive at the clinic 90 min prior to their scheduled visit to review study information with the CRA, provide informed consent, complete pre- and post-test and post-clinical encounter surveys, and the PSCPrep. The day prior to their scheduled visit, the CRA will call to remind them of their appointment and the opportunity to participate in this study.
INTERVENTION ADMINISTRATION PCSPrep meets the International Patient Decision Aid Standards for high quality DAs, and adheres to best practices for culturally relevant interventions.Learning objectives for participants include to: (1) understand that there is a decision to be made; (2) identify their preferred role in decision-making; (3) obtain accurate, unbiased information about benefits, limitations and potential harms of screening; (4) understand personal risk of CaP; (5) clarify one's values as they relate to the potential screening outcomes; (6) seek input from significant others, if desired; (7) develop skills for communicating with provider; (8) elicit input from provider; and (9) develop a plan for action based on desired course of action.
PCSPrep uses an audiovisual and touch-screen format on an iPad to simplify use for individuals with limited literacy and/or computer skills. It is comprised of a series of modules on the web in which professional actors describe the decision-making process, communication with a provider, and discussion of PCS. Content is delivered by actors presented as physicians who answer call-in questions in a format modeled on a health-focused television show, based on focus group feedback. Questions and discussion are presented to normalize the idea that decisions are based on individual values and preferences.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Medford, Massachusetts, United States, 02155
- Tufts University
-
-
Virginia
-
Atlanta, Virginia, United States
- Emory University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- African american men,
- ages 45-70 who are able to provide informed consent to participate in the educational intervention and associated data collection activities.
- English speaking
Exclusion Criteria:
- no prior personal history of prostate cancer
- no prior prostate cancer screening with the prostate specific antigen test within preceding three years
- inability to speak English
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PCSPrep decision aid
All participants recruited to the trial will receive the decision aid.
This a one-group study with a quasi-experiemental pre/post evaluation design.
|
All patients recruited to the study will receive the PCSPrep decision aid.
There is only 'study arm.'
The Clinical Research Coordinator (CRC) will provide the patient with an iPad to complete the pre-test, PCSPrep and post-test.
Individuals will see the survey questions on screen and will hear accompanying audio through headsets.
Participants will: (1) be introduced to PCSPrep and the menu of activities/topics; (2) enter information about themselves for personal tailoring (e.g., risk factors); (3) participate in a values-clarification exercise to rate the personal importance of varied courses of action (i.e., pros/cons of PCS); (4) receive a printout with an individualized plan for discussing PCS with their primary care provider.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Decision self-efficacy
Time Frame: Baseline (T0) upon enrollment into study; immediately following use of decision aid (PCSPrep) approx 30 min after baseline (T1); approximately one hour later, after visiting with primary care provider (T3)
|
Confidence in ones ability to gather requisite information and to make an informed decision
|
Baseline (T0) upon enrollment into study; immediately following use of decision aid (PCSPrep) approx 30 min after baseline (T1); approximately one hour later, after visiting with primary care provider (T3)
|
Prostate cancer screening knowledge
Time Frame: Baseline (T0) upon enrollment into study; immediately following use of decision aid (PCSPrep) approximately 30 minutes after baseline (T1)
|
Knowledge regarding the potential benefits, harms and limitations of prostate cancer screening
|
Baseline (T0) upon enrollment into study; immediately following use of decision aid (PCSPrep) approximately 30 minutes after baseline (T1)
|
Decisional consistency
Time Frame: Baseline (T0) upon enrollment into study; immediately following use of decision aid (PCSPrep) approx 30 min after baseline (T1); approximately one hour later, after visiting with primary care provider (T3)
|
Consistency between decision about screening and stated values regarding the pros and cons of screening
|
Baseline (T0) upon enrollment into study; immediately following use of decision aid (PCSPrep) approx 30 min after baseline (T1); approximately one hour later, after visiting with primary care provider (T3)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jennifer D Allen, SCD, Tufts University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1309011
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Neoplasm
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMalignant Solid Neoplasm | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedProstatic Neoplasms | Prostate Cancer | Neoplasm, Prostate | Neoplasm,ProstaticUnited States
-
University of Wisconsin, MadisonProstate Cancer Foundation; Madison Vaccines, IncCompletedMetastatic Prostate Carcinoma | Prostate Adenocarcinoma | Metastatic Malignant Neoplasm in the Bone | Metastatic Malignant Neoplasm in the Soft Tissues | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate CancerUnited States
-
Aarhus University HospitalKarolinska University Hospital; Karolinska Institutet; University of Aarhus; Central... and other collaboratorsUnknownProstate Cancer | Prostate Adenocarcinoma | Prostate NeoplasmDenmark
-
Cambridge University Hospitals NHS Foundation TrustUniversity of CambridgeSuspendedProstate Cancer | Prostate NeoplasmUnited Kingdom
-
Case Comprehensive Cancer CenterNational Institutes of Health (NIH)Not yet recruitingProstate Cancer | Malignant Neoplasm of Prostate | Secondary Malignant Neoplasm of ProstateUnited States
-
Postgraduate Institute of Medical Education and...RecruitingProstate Cancer | Prostate NeoplasmIndia
-
University College, LondonRecruitingProstate Cancer | Prostate NeoplasmUnited Kingdom
-
Crozer-Keystone Health SystemRecruitingProstate Cancer | Prostate Adenocarcinoma | Prostate NeoplasmUnited States
-
University of UtahActive, not recruitingProstate Adenocarcinoma | Metastatic Malignant Neoplasm in the Bone | Metastatic Malignant Neoplasm in the Lymph Nodes | Recurrent Prostate Carcinoma | Oligometastasis | PSA FailureUnited States
Clinical Trials on Prostate Cancer Screening Decision Aid
-
Case Comprehensive Cancer CenterCompletedProstate CancerUnited States
-
Centers for Disease Control and PreventionUnknownProstate CancerUnited States
-
University of PennsylvaniaCompletedBreast CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterUNC Cecil G. Sheps Center for Health Services ResearchCompletedNeoplasm of Lung | Decision Support Techniques | Mass ScreeningUnited States
-
Reykjavik UniversityThe Icelandic Research Fund; The Icelandic Cancer SocietyCompleted
-
University of SydneyNational Health and Medical Research Council, AustraliaUnknownColorectal NeoplasmsAustralia
-
UNC Lineberger Comprehensive Cancer CenterCompletedColorectal CancerUnited States
-
Pontificia Universidad Catolica de ChileComisión Nacional de Investigación Científica y TecnológicaRecruitingBreast Cancer | Breast Tumor | Mammary Cancer | Mammary TumorChile
-
Institut de Recerca Biomèdica de LleidaInstitut Català d'Oncologia; Hospital del Mar; Canary Islands Health ServiceCompletedBreast Cancer ScreeningSpain
-
UNC Lineberger Comprehensive Cancer CenterCompletedLung Neoplasms | Primary Health Care | Decision Support Techniques | Early Detection of CancerUnited States